High Purity Elvitegravir (CAS 697761-98-1) - Advanced HIV Integrase Inhibitor | Supplier in China

Discover Elvitegravir, a critical quinolone-class integrase inhibitor essential for advanced HIV/AIDS treatment. As a trusted manufacturer and supplier, we offer high-purity Elvitegravir (CAS 697761-98-1), supporting pharmaceutical development with reliable sourcing and competitive pricing. Request your quote and sample today to experience our commitment to quality.

Get a Quote & Sample

Advantages of Partnering With Our Elvitegravir Supply

Exceptional Purity & Quality Assurance

We guarantee Elvitegravir with ≥99% purity (HPLC), ensuring it meets stringent pharmaceutical requirements. As a trusted manufacturer, our rigorous quality control processes are paramount for your product's success.

Reliable Supply Chain & Competitive Pricing

Secure a consistent and cost-effective supply of Elvitegravir (CAS 697761-98-1) from our China-based facility. We cater to bulk purchase orders, offering competitive prices for manufacturers worldwide.

Expertise in Pharmaceutical Intermediates

Leverage our deep understanding of pharmaceutical intermediates. We are dedicated to supporting your R&D and production with high-grade APIs like Elvitegravir, facilitating your access to essential antiviral compounds.

Key Applications of Elvitegravir

HIV/AIDS Treatment Formulations

Elvitegravir is a vital component in combination therapies for HIV/AIDS, acting as an integrase inhibitor to effectively manage viral replication.

Pharmaceutical Research & Development

Its specific chemical properties and therapeutic action make Elvitegravir a critical compound for ongoing research into antiviral drug efficacy and development.

Antiviral Drug Manufacturing

As a high-purity API, Elvitegravir is indispensable for the precise manufacturing of advanced antiviral medications by pharmaceutical companies globally.

Chemical Synthesis Intermediates

Elvitegravir serves as a crucial intermediate in complex chemical synthesis pathways, supporting the creation of novel therapeutic agents.